Top Pharmaceutical Company Rolls Out Enterprise Solution Globally to Increase Clinical Trial Efficiencies
New York, USA - April 11, 2005 - Medidata Solutions Inc., a leading provider of electronic clinical data management solutions conducting trials in over 40 countries, today announced that it has signed a multi-year technology license agreement with Bayer HealthCare AG (BHC). For its Phase I-IV clinical trials globally, BHC is standardizing its method of capturing clinical trial data on Medidata's RAVE solution, a strategic decision aimed at increasing clinical trial efficiencies.
"Bayer HealthCare views electronic clinical data management as an important component of our global focus on increasing clinical trial capacity while managing costs through standardizing on a common platform," said Dr. Johann Prove, Head of Data Acquisition and Data Management at Bayer HealthCare, based in Germany. "A cross-functional team evaluated our alternatives, both internal and external, and concluded that Medidata's RAVE solution provided all markets with the most adaptable and extensive capabilities to drive business value and common processes globally."
Using Medidata RAVE, Bayer HealthCare expects that 100% of its internally managed clinical trials will implement electronic data capture (EDC), thus benefiting from improved data quality and earlier access to data versus traditional paper-based clinical trials. BHC will also benefit from more appropriate resource allocation, earlier decision-making during all phases of clinical studies and shorter cycle times between follow-on studies.
"Time to market is a critical factor for leading pharmaceutical companies, and Medidata RAVE provides BHC with the opportunity to increase clinical trial capacity through optimal use of resources, while simultaneously lowering overall R&D costs." said Glen de Vries, CTO Medidata Solutions. "Bayer Healthcare recognizes that the scalability, flexibility, and functionality of Medidata technology coupled with Medidata's expertise in managing clinical trials are key elements for a global electronic data management solution."
Bayer HealthCare has committed to conducting over 150 clinical studies on Medidata RAVE in the next three years, with the first wave of clinical studies to be started in June 2005. IBM Global Services guided the software evaluation process that resulted in the selection of Medidata RAVE and will support its implementation at BHC. "Working with Bayer HealthCare and Medidata to implement a global business solution delivers on our core objective of combining IBM's global service capabilities with industry-leading software vendors, like Medidata, to provide end-to-end solutions and increased efficiencies from technology implementations to our clients", said Sven Blumenstiel, IBM Business Consulting Services. "By providing a range of services including process re-engineering, validation support and program management support, IBM is pleased to play a key role in the deployment and success of the Medidata RAVE solution at Bayer HealthCare."
With this agreement the German pharmaceutical company has joined a growing number of leading pharmaceutical companies that have chosen Medidata's technology for use on an enterprise-wide basis. Tarek Sherif, CEO of Medidata notes that, "Bayer HealthCare's decision to adopt our technology for use in clinical studies, reflects a growing trend to standardize company-wide on a single technology and reap the improved economy and effectiveness of common processes and streamlined analytics".
About Medidata Solutions
Medidata Solutions understands and helps clients manage the business of electronic clinical data management better than any one else. Designed to reduce the latency of information flow, optimize decision-making and improve resource allocation and safety, Medidata Solutions' flexible, enterprise-class workflow and web-based technology assists global life sciences and research organizations to accelerate the process of bringing life-enhancing treatments to market. Streamlined collection, verification, consolidation and analysis of clinical research data gives front line investigators, data managers and executives powerful tools to make more precise decisions earlier, reduce costs and drive efficiency. To learn more about Medidata Solutions visit www.mdsol.com.
About Bayer Healthcare AG
Bayer HealthCare AG, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the health care and medical products industry. In 2004, the Bayer HealthCare subgroup generated sales amounting to some 8.5 billion Euro. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide in 2004.Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating disease.
www.bayer.com
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.